Abstract:Chromogenic in situ hybridization (CISH) has shown the potential to replace fluorescence in situ hybridization (FISH) to determine HER2 gene status. To validate the reliability of CISH, we used 226 consecutive breast carcinomas from 2 institutions and tested CISH and FISH on the same tumor set simultaneously at different test sites. Besides manufacturers’ scoring criteria, the new American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines were used to interpret HER2 status. The concordance between CISH and FISH for positive and negative results was 98.5% at site A and 98.6% at site B using the manufacturers’ criteria, and 99.0% at site A and 99.1% at site B using the ASCO/CAP criteria. Reproducibility of CISH results was more than 98.0% among 3 sites using the manufacturers’ criteria and 100.0% between 2 sites using the ASCO/CAP criteria. Our results confirm that CISH is reliable for HER2 testing per ASCO/CAP guidelines. Identification of human epidermal growth factor receptor 2 (HER2) status is important to making therapeutic decisions for patients with breast cancer, both at the time of initial diagnosis and at recurrence. Positive HER2 status (ie, overexpression of the HER2 protein or amplification of the HER2 gene) has been reported in approximately 15% to 20% of women with newly diagnosed breast cancers1,2 and is associated with a poor clinical outcome, resistance to hormone therapy, and resistance to certain types of chemotherapy.3-7 More important, positive HER2 status is a strong predictor of response to anti-HER2 therapies, such as trastuzumab (Herceptin), and, therefore, is a major criterion for patient selection for HER2-targeted therapies.8-15 However, trastuzumab therapy is expensive16 and associated with rare but severe cardiotoxic effects.8,15,17,18 Accurate HER2 testing allows oncologists to administer timely anti-HER2 therapy to patients who may benefit and to spare patients who would not benefit from the costly and potentially harmful regimen. Various methods of assessing gene amplification, messenger RNA level, and protein expression have been used to determine HER2 status in breast cancer, including Southern, Northern, and Western blots; polymerase chain reaction; and enzyme-linked immunosorbent assay. Immunohistochemical analysis and fluorescence in situ hybridization (FISH) are the 2 methods most widely used to determine HER2 status in the routine diagnostic setting. Each method has advantages and disadvantages. Immunohistochemical analysis measures HER2 protein expression on the cell surface and is easy to conduct in most pathology laboratories. However, the result of immunohistochemical staining is relatively susceptible to variations in tissue fixation and processing. Approximately 20% of HER2 protein tests performed in the local pathology

Differential Expression and Its Clinical Significance of Amplification in Her-2 Gene and Protein with Breast Cancer

A Comparative Study on HER-2 Expression by Immunohistochemistry and Fluorescence in Situ Hybridization in Breast Cancer Tissue

HER2 Gene Amplification by Fluorescence In Situ Hybridization (FISH) Compared With Immunohistochemistry (IHC) in 122 Equivocal Gastric Cancer Cases.

Evaluation of HER2 Oncogene Amplification and Overexpression in Breast Cancer and Their Clinical Significance

Comparision of HER2/neu Oncogene Detected by Chromogenic In-Situ Hybridization and Immunohistochemistry in Breast Cancer

HER2 Protein Expression Level is Positively Associated with the Efficacy of Neoadjuvant Systemic Therapy in HER2-positive Breast Cancer

[Analysis of HER2 Gene Amplification and Its Protein Expression in 165 Cases of Breast Carcinoma: Comparison of Chromogenic In-Situ Hybridization and Immunohistochemistry].

Consistency of HER-2 Expression Detected by Both Immunohistochemistry and Fluorescence in Situ Hybridization in Gastric Cancer

Human Epidermal Growth Factor Receptor 2 Protein Expression Between Primary Breast Cancer and Paired Asynchronous Local-Regional Recurrences.

Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients

[Assessment of HER2 Gene Amplification in Breast Cancer: a Comparison of Dual-Color In-Situ Hybridization and Fluorescence In-Situ Hybridization].

An Analysis of HER2 Amplification in Cervical Adenocarcinoma: Correlation with Clinical Outcomes and the International Endocervical Adenocarcinoma Criteria and Classification

Comparison between analysis of HER2 gene and chromosome 17 in breast cancer by dual-probe chromogenic in situ hybridization and fluorescence in situ hybridization

HER2 Overexpression/amplification Status in Colorectal Cancer: a Comparison Between Immunohistochemistry and Fluorescence in Situ Hybridization Using Five Different Immunohistochemical Scoring Criteria

Determination of HER2 Gene Amplification by Chromogenic in Situ Hybridization (CISH) in Archival Breast Carcinoma.

HER2 Changes to Positive after Neoadjuvant Chemotherapy in Breast Cancer: A Case Report and Literature Review

Chromogenic in Situ Hybridization is a Reliable Method for DetectingHER2Gene Status in Breast Cancer

Genetic Alterations and Protein Expression of HER2 and Chromosome 17 Polysomy in Breast Cancer

Egfr and Her2 Expression in Primary Cervical Cancers and Corresponding Lymph Node Metastases: Implications for Targeted Radiotherapy

HER-2 gene amplification and protein expression in esophageal squamous cell carcinoma

The effect of different expression levels of HER-2 on the biological characteristics of breast cancer cells